Results from the single-arm trial saw 63.5% of patients able to avoid the symptoms of Atrial fibrillation over the course of ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.

The FDA has granted approval for Zydus to proceed with the Phase II(b) trial of Usnoflast for amyotrophic lateral sclerosis (ALS) treatment.

Palisade Bio has begun the multiple ascending dose (MAD) cohorts of its ongoing Phase Ia/b trial of PALI-2108 for ulcerative ...

Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

The company said that all of its CONNEX trials failed to meet expectations showing no impact on patients living with ...

Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.

Pfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.